Halozyme Cash Flow Statement
HALO / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Halozyme generated $652M in operating cash flow and $645M in free cash flow in FY2025. Free cash flow margin was 46.2% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $316.9M | $444.1M | $281.6M | $202.1M | -$72.2M | -$80.3M | $63.0M | -$80.3M | $63.0M | -$68.4M | -$83.5M | -$53.6M | -$83.5M | -$53.2M | -$19.8M |
| Depreciation & Amortization | $11.4M | $10.3M | $11.1M | $6.5M | $4.1M | $2.4M | $2.2M | $2.4M | $2.2M | $1.8M | $1.2M | $1.1M | $1.2M | $1.5M | $1.1M |
| Operating Cash Flow | $651.6M | $479.1M | $388.6M | $240.1M | -$85.4M | -$49.5M | $134.1M | -$49.5M | $134.1M | -$47.5M | -$49.3M | -$64.3M | -$49.3M | -$45.4M | -$34.3M |
| Capital Expenditures | $7.0M | $10.7M | $15.3M | $4.8M | $4.0M | $4.7M | $1.4M | $4.7M | $1.4M | $1.4M | $2.3M | $1.4M | $2.3M | $646.5K | $828.5K |
| Free Cash Flow | $644.6M | $468.4M | $373.3M | $235.3M | -$89.5M | -$54.2M | $132.7M | -$54.2M | $132.7M | -$48.9M | -$51.6M | -$65.7M | -$51.6M | -$46.0M | -$35.1M |
| Share Buybacks | $342.4M | $250.0M | $402.4M | $200.0M | $200.0M | $0 | $0 | $0 | $0 | - | - | - | - | - | - |
| FCF Margin | 46.2% | 46.1% | 45.0% | 35.6% | -45.6% | -35.7% | 233.0% | -175.4% | 41.9% | -64.9% | -94.2% | -155.2% | -94.2% | -337.9% | -62.6% |